| Clinical Manifestations of Steroid-associated Central Serous Chorioretinopathy. |
|
Sung Won Choi, Yu Cheol Kim |
|
Department of Ophthalmology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea. eyedr@damc.or.kr |
| 스테로이드 사용 후 발생한 중심장액맥락망막병증의 임상양상 비교 |
|
최성원⋅김유철 |
|
계명대학교 의과대학 동산의료원 안과학교실 |
Correspondence:
Yu Cheol Kim,
Email: eyedr@damc.or.kr
|
|
Received: 9 November 2017 • Revised: 13 January 2018 • Accepted: 29 March 2018 |
| Abstract |
PURPOSE
To evaluate the clinical differences between patients with central serous chorioretinopathy (CSC) developed after steroid use and CSC patients without a history of steroid use for short-term periods. METHODS: We retrospectively analyzed the medical records of 47 patients (55 eyes) diagnosed with CSC from January 2011 to August 2017 by categorizing Group 1 (32 patients, 36 eyes) without a history of steroid use and Group 2 (15 patients, 19 eyes) with a history of steroid use within 6 months. We evaluated the differences in best-corrected visual acuity (BCVA), subretinal fluid (SRF) height, subfoveal choroidal thickness (SFCT), and Haller's layer thickness in the two groups. We also analyzed the changes in the BCVA, SRF height, SFCT, and Haller’s layer thickness in each group for 1 month and compared them depending on the treatment. RESULTS: There were no significant differences between the two groups with regard to age, sex, BCVA, bilaterality, number of leakage points, and Haller's layer thickness. Group 2 showed significantly increased SRF height and SFCT than Group 1 (p = 0.002, p = 0.005, respectively). In Group 1, the level of SRF and SFCT were significantly more decreased after 1 month (p = 0.001, 0.015, respectively) in patients with treatment than in those without treatment. In Group 2, the height of the SRF and SFCT were significantly more decreased after 1 month (p = 0.005, 0.002, respectively) in untreated patients compared to treated patients. CONCLUSIONS: CSC patients with a prior history of steroid use have higher serous detachment and a thicker SFCT than those without prior history of steroid use. Therefore, termination of steroid treatment may reduce the SFCT and SRF in steroid-treated CSC patients. |
| Key Words:
Central serous chorioretinopathy;Choroidal thickness;Steroid;Subretinal fluid |
|
PDF Links
Full text via DOI
Download Citation
